Dilution Overwhelms Top-Line Gains, Threatening Per-Share Value

What happened

Tilray's fiscal Q4 revenue grew strongly thanks to the BrewDog acquisition, but shares hit new lows as ongoing equity dilution erased any benefit from top-line expansion. Most segment gross margins stagnated, and adjusted net income plunged 60% year-over-year, spotlighting persistent profitability challenges despite scaling revenue. The beverage segment, while boosted by BrewDog, continues to suffer margin compression, and the core cannabis business remains under Canadian price pressure. With the share count ballooning from ATM sales, per-share metrics are deteriorating even as headline revenue rises, leaving investors increasingly skeptical that the diversified strategy will ever yield sustainable returns. The stock's depressed valuation relative to Canopy Growth reflects a market that no longer rewards scale without proof of durable cash generation, and the current trajectory points to further value erosion unless the capital structure is stabilized immediately.

Implication

With revenue growth failing to translate into bottom-line improvement and the share count swelling, Tilray's investment case increasingly depends on bold regulatory tailwinds like U.S. rescheduling or EU legalization that remain uncertain and distant. The beverage acquisition strategy has not delivered margin accretion, and the core cannabis business faces structural headwinds, making the path to sustainable profitability harder. Investors should demand clear evidence of sustained positive operating cash flow and a halt to dilution before considering entry, as the current trajectory points to further value erosion. The depressed valuation versus Canopy Growth reflects market recognition that Tilray's scale has not yielded profitability, and without a sharp reversal in fundamentals, the stock will remain a high-risk, policy-driven trade rather than a long-term compounder. The WAIT rating is maintained, but the threshold for an upgrade is now higher—requiring not just improving EBITDA but durable cash flow and a clear path to stemming dilution.

Thesis delta

The new quarterly evidence shifts our view incrementally more cautious. The gap between revenue growth and shareholder returns has widened, with dilution now a central risk that was previously underappreciated. Our base-case implied value drifts lower to $9, reflecting a higher probability that per-share metrics will continue to deteriorate unless management can fund operations internally and reduce equity issuance.